OBJECTIVE: Preliminary observations by a single pathologist at our institution revealed a 75% incidence of villitis of unexplained etiology in ovum donor in vitro fertilization pregnancies. Because the incidence of villitis of unexplained etiology in the general population is approximately 10%, we conducted a controlled study to compare the incidence of villitis of unexplained etiology in ovum donor in vitro fertilization pregnancies to that in in vitro fertilization pregnancies that do not use donated ova. STUDY DESIGN:Placental specimens of ovum donor in vitro fertilization pregnancies were matched randomly with pregnancies that resulted from both fresh and frozen/thawed native oocyte in vitro fertilization from March 5, 1995, to October 10, 2001, and examined in a blinded fashion by a single pathologist (D. J. R.) for villitis of unexplained cause. The incidence of villitis of unexplained etiology was analyzed in 27 patients who underwent ovum donor in vitro fertilization versus 37 patients who underwent native oocyte in vitro fertilization. RESULTS:Villitis of unexplained cause occurred in 22.2% of ovum donor in vitro fertilization pregnancies, 10.8% of native oocyte in vitro fertilization pregnancies (fresh and frozen/thawed combined), and 14.3% of frozen/thawed cycles (P=.21). CONCLUSION: Although the incidence was not statistically different than in in vitro fertilization that used native maternal oocytes, there was a 2-fold increase in villitis of unexplained cause in the ovum donor in vitro fertilization placentas, which suggests that immune-related disorders may be increased in ovum donor pregnancies.
RCT Entities:
OBJECTIVE: Preliminary observations by a single pathologist at our institution revealed a 75% incidence of villitis of unexplained etiology in ovum donor in vitro fertilization pregnancies. Because the incidence of villitis of unexplained etiology in the general population is approximately 10%, we conducted a controlled study to compare the incidence of villitis of unexplained etiology in ovum donor in vitro fertilization pregnancies to that in in vitro fertilization pregnancies that do not use donated ova. STUDY DESIGN: Placental specimens of ovum donor in vitro fertilization pregnancies were matched randomly with pregnancies that resulted from both fresh and frozen/thawed native oocyte in vitro fertilization from March 5, 1995, to October 10, 2001, and examined in a blinded fashion by a single pathologist (D. J. R.) for villitis of unexplained cause. The incidence of villitis of unexplained etiology was analyzed in 27 patients who underwent ovum donor in vitro fertilization versus 37 patients who underwent native oocyte in vitro fertilization. RESULTS:Villitis of unexplained cause occurred in 22.2% of ovum donor in vitro fertilization pregnancies, 10.8% of native oocyte in vitro fertilization pregnancies (fresh and frozen/thawed combined), and 14.3% of frozen/thawed cycles (P=.21). CONCLUSION: Although the incidence was not statistically different than in in vitro fertilization that used native maternal oocytes, there was a 2-fold increase in villitis of unexplained cause in the ovum donor in vitro fertilization placentas, which suggests that immune-related disorders may be increased in ovum donor pregnancies.
Authors: Elizabeth Ann L Enninga; Patrick Raber; Reade A Quinton; Rodrigo Ruano; Nadia Ikumi; Clive M Gray; Erica L Johnson; Rana Chakraborty; Sarah E Kerr Journal: J Immunol Date: 2020-04-22 Impact factor: 5.422
Authors: Elizabeth Ann L Enninga; Alexey A Leontovich; Bohdana Fedyshyn; Laurie Wakefield; Manish Gandhi; Svetomir N Markovic; Rodrigo Ruano; Sarah E Kerr Journal: Reprod Sci Date: 2020-01-06 Impact factor: 3.060
Authors: Linda M Ernst; Crystal Bockoven; Alexa Freedman; Vivien Wang; Matthew Pellerite; Todd N Wylie; Kristine M Wylie Journal: Placenta Date: 2021-03-01 Impact factor: 3.481
Authors: Raymond W Redline; Sanjita Ravishankar; Christina M Bagby; Shahrazad T Saab; Shabnam Zarei Journal: Mod Pathol Date: 2021-02-08 Impact factor: 8.209
Authors: Maryam Shahi; Ricardo Mamber Czeresnia; E Heidi Cheek; Reade A Quinton; Rana Chakraborty; Elizabeth Ann L Enninga Journal: Front Immunol Date: 2021-07-30 Impact factor: 7.561